Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 10

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 10
---
 proceeds for general corporate purposes and working capital.

Yorkville’s obligation to purchase common shares pursuant to the SEPA is subject to a number of conditions, including that the Company file a registration statement (the “Registration Statement”) with the SEC registering the resale of the Commitment Shares (as defined below) and the common shares. The Company is required to have a Registration Statement declared effective by the SEC before it can sell any common shares to Yorkville pursuant to the SEPA.

The total number of common shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding common shares as of the date of the SEPA unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to the Company under the SEPA. The issuance of common shares under the SEPA is subject to further limitations, including that the common shares beneficially owned by Yorkville and its affiliates at any one time will not exceed 4.99% of the then-outstanding common shares.

As consideration for Yorkville’s commitment to purchase common shares pursuant the SEPA, the Company paid Yorkville a structuring fee in the amount of $25,000 and issued to Yorkville 105,840 common shares (the “Commitment Shares”).

Submission of Phase 2 Clinical Design (SKNJCT-004) to the United Arab Emirates Department of Health

On February 27, 2025, the Company announced that it had submitted a clinical design (SKNJCT-004) to the United Arab Emirates Department of Health to non-invasively treat BCC of the skin. The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The study is expected to randomize thirty-six (36) patients in four sites in the UAE.

Implications of Being an Emerging Growth Company

As a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an "emerging growth company"